Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4405 ARTÍCULOS , VIENDO DEL 2746 AL 2760

Glucose Hypermetabolism in Contralateral Basal Ganglia Demonstrated by Serial FDG PET/CT Scans in a Patient With SLE Chorea

Niu N, Cui R.

Clin Nucl Med. 2017 Jan;42(1):64-65. doi: 10.1097/RLU.0000000000001450.

Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease

Simmons DA, Longo FM, Massa SM.

CNS Neurol Disord Drug Targets. 2017;16(3):291-302. doi: 10.2174/1871527315666161107093047.

Glucose Transporters in Brain: In Health and in Alzheimer's Disease

Szablewski L.

J Alzheimers Dis. 2017;55(4):1307-1320. doi: 10.3233/JAD-160841.

Neurotrophin signalling: novel insights into mechanisms and pathophysiology

Mitre M, Mariga A, Chao MV.

Clin Sci (Lond). 2017 Jan 1;131(1):13-23. doi: 10.1042/CS20160044.

A case of severe movement disorder with GNAO1 mutation responsive to topiramate

Sakamoto S, Monden Y, Fukai R, Miyake N, Saito H, Miyauchi A, Matsumoto A, Nagashima M, Osaka H, Matsumoto N, Yamagata T.

Brain Dev. 2017 May;39(5):439-443. doi: 10.1016/j.braindev.2016.11.009. Epub 2017 Jan 6.

Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies

Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC.

Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):a024240. doi: 10.1101/cshperspect.a024240.

Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease

Coppen EM, Roos RA.

Drugs. 2017 Jan;77(1):29-46. doi: 10.1007/s40265-016-0670-4.

Urate as a Marker of Risk and Progression of Neurodegenerative Disease

Paganoni S, Schwarzschild MA.

Neurotherapeutics. 2017 Jan;14(1):148-153. doi: 10.1007/s13311-016-0497-4.

Synopsis on Managment Strategies for Neurodegenerative Disorders: Challenges from Bench to Bedside in Successful Drug Discovery and Development

Bhat SA, Kamal MA, Yarla NS, Ashraf GM.

Curr Top Med Chem. 2017;17(12):1371-1378. doi: 10.2174/1568026616666161222121229.

Management of Neuropsychiatric Symptoms in Neurocognitive Disorders

Legesse B, Babadi B, Forester B.

Focus (Am Psychiatr Publ). 2017 Jan;15(1):18-25. doi: 10.1176/appi.focus.20160031. Epub 2017 Jan 11.

Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration

Shaffer JJ, Ghayoor A, Long JD, Kim RE, Lourens S, O'Donnell LJ, Westin CF, Rathi Y, Magnotta V, Paulsen JS, Johnson HJ.

Hum Brain Mapp. 2017 Mar;38(3):1460-1477. doi: 10.1002/hbm.23465. Epub 2017 Jan 3.

Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants

Hassan W, Noreen H, Rehman S, Gul S, Kamal MA, Kamdem JP, Zaman B, da Rocha JBT.

Curr Top Med Chem. 2017;17(12):1336-1370. doi: 10.2174/1568026617666170102125648.

Functional Prions in the Brain

Rayman JB, Kandel ER.

Cold Spring Harb Perspect Biol. 2017 Jan 3;9(1):a023671. doi: 10.1101/cshperspect.a023671.

Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal

Romano A, Serviddio G, Calcagnini S, Villani R, Giudetti AM, Cassano T, Gaetani S.

Free Radic Biol Med. 2017 Oct;111:281-293. doi: 10.1016/j.freeradbiomed.2016.12.046. Epub 2017 Jan 4.

When proteostasis goes bad: Protein aggregation in the cell

Radwan M, Wood RJ, Sui X, Hatters DM.

IUBMB Life. 2017 Feb;69(2):49-54. doi: 10.1002/iub.1597. Epub 2017 Jan 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias